13.9% Average Loss With Semaglutide in Obesity and Prediabetes

STEP 10 found semaglutide 2.4 mg produced 13.9% average weight loss at 52 weeks in adults with obesity and prediabetes, with study context and limits.

At week 52, mean body-weight change was −13.9% with semaglutide and −2.7% with placebo.

207 adults with obesity (BMI of at least 30) and prediabetes defined by the trial's HbA1c or fasting-glucose criteria; 52-week treatment period; 80 weeks including the off-treatment follow-up. Read the linked peer-reviewed source for the full methodology, findings, and limitations.

McGowan et al., Lancet Diabetes & Endocrinology 2024 · STEP 10